CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs
|
|
- Roderick Walsh
- 5 years ago
- Views:
Transcription
1 CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs Meg Doherty, Treatment and Care Coordinator WHO HQ
2 Outline What s new in ARV Guidelines Drug optimisation PADO priority list 2015 CROI 2016 Think Thank Meeting EOI 2016 list HIVDR Moving forward
3 Outline What s new in ARV Guidelines Drug optimisation PADO priority list 2015 CROI 2016 Think Thank Meeting EOI 2016 list HIVDR Moving forward
4 Key messages from the 2015 WHO ARV guidelines Treat all (at any CD4) - PLHIV across all ages, but the sickest remain a priority (symptomatic disease and CD4 < 350). Phased introduction of optimized regimens (new drug class; optimized dosing and formulations) Care packages to optimize the care cascade (reduce late presentation, improve retention). PrEP recommended as an additional prevention choice for all people at substantial risk of HIV infection.
5 PLHIV Evolution of global ART coverage and eligibility criteria according WHO guidelines ( ) at any CD4 not elegible CD4 < elegible but not on ART CD4 < on ART CD4 < 200 3% CD4 < % 21% 36% At CD4 < 350: active TB disease and HIV+ pregnant women 2. At any CD4: active TB disease and HBV co-infection requiring HBV treatment 3. At any CD4: active TB disease, HBV co-infection with severe liver disease, HIV+ pregnant women and HIV serodiscordant couples 43% Source WHO rand UNAIDS reports
6 Global number of PLHIV Treatment gap based on 2013 WHO ART guidelines (CD4 < 500) PLHIV currently on ART Treatment Gap ~ 37 million +9 million +13 million 16 million +21 million Treatment gap with expanded eligibility criteria (Treat all) Cost 31 billion USD per year by 2020; 50% treatment cost
7 Summary of sequencing options for major first-, second- and third-line ART regimens in adults, adolescents, pregnant women and children Population 1 st line regimens 2 nd line regimens 3 rd line regimens Adults and adolescents Pregnant/breastf eeding women Children 2 NRTIs + EFV 2 NRTIs + DTG 2 NRTIs + EFV 2 NRTI + LPV/r 2 NRTIs + ATV/r or LPV/r DRV/r + DTG (or RAL) ± NRTI + DRV/r NRTIs Adults and adolescents: Preferred 1 st and 2 nd line remains the same 2 NRTIs ; + new ATV/r options or LPV/r as DRV/r alternatives + 2 NRTIs ± in NNRTI 1 st line (DTG and EFV 400 ) and 2 nd line (RAL and DRV/r) 2 NRTI + EFV 2 NRTI + DRV/r 08/03/ Optimize regimen using genotype profile 2 NRTIs + ATV/r or LPV/r DRV/r + DTG (or RAL) ± NRTI + DRV/r NRTIs Pregnant women: Like adults (except DTG & EFV 400 ) If less than 3 years: 2 NRTI + RAL If older than 3 years: DTG + 2 NRTIs DRV/r + 2 NRTIs 2 NRTI + EFV or RAL DRV/r + DTG ± 1-2 NRTIs Infants and children: No changes in 1 st line; more options for 2 nd line (RAL and expanded age for ATV/r) 2 NRTIs + ATV/r c or LPV/r
8 Safety and Efficacy of INSTIs and EFV 400 in 1 st line ART (using network metanalysis) major outcomes INSTI vs EFV 600 DTG vs other INSTI DTG vs EFV 600 DTG vs EFV 400 EFV 400 vs EFV 600 QUALITY OF EVIDENCE Viral suppression INSTI better DTG better DTG better comparable 1 comparable moderate CD4 recovery INSTI better DTG better DTG better comparable EFV 400 better moderate Treatment discontinuation INSTI better DTG better DTG better comparable EFV 400 better moderate Mortality comparable comparable comparable comparable comparable low AIDS progression comparable comparable comparable comparable comparable low SAE comparable comparable comparable comparable comparable moderate 1 Estimated effects favored DTG but statistical analysis not significant WHO, 2015
9 Safety and Efficacy of DRV/r and INSTI/PI regimens in 2 nd line ART (NMA) major outcomes DRV/r vs ATV/r or LPV/r DRV 800 OD vs DRV 600 OD DRV 800/100 OD vs DRV 600/100 BD RAL + LPVr vs 2 NRTIs + ATVr or LPV/r QUALITY OF EVDIENCE Viral suppression CD4 recovery Comparable comparable 3 comparable 1 equivalent moderate comparable comparable comparable 2 comparable 4 low Treatment discontinuation comparable comparable 3 comparable 2 comparable low Mortality AIDS progression SAE comparable comparable comparable 2 comparable low comparable comparable comparable 2 comparable low comparable comparable comparable 2 comparable low 1 Confidence interval too large to establish equivalence 2 Estimated effects favored DRV/r 800/100 but statistical analysis not significant 3 Estimated effects favored DRV/r 800/100 but statistical analysis not significant 4 Estimated effects favored LPV/r + RAL but statistically not significant WHO, 2015
10 Outline What s new in ARV Guidelines Drug optimisation PADO priority list 2015 CROI 2016 Think Thank Meeting EOI 2016 list HIVDR Moving forward
11 ARV Drug Optimization: Key Principles Reduce toxicity Improve palatability/pill burden Increase durability Improve sequencing Harmonization across different age groups and populations Reduce cost
12 PADO 2 priorities DRVr & ATVr ABC/3TC/EFV FORMULATIONS of existing ARVs LPV r 4 in 1 Identifying priority regimens for optimal sequencing which include newer compounds for which paediatric development has not been completed RAL DTG 0-3 yrs 3-10 yrs 10 yrs + NVP 20 mg FIRST LINE Mid-term (5 yr) ABC/3TC/DTG TAF/3TC/DTG New formulations of existing drugs that already have registration for children or in advanced paediatric development Long term (10 yr) TAF/3TC/DTG SECOND LINE Mid-term (5 yr) AZT/3TC/RAL or LPV/r AZT/3TC/DRV/r TAF/3TC/DRV/r Long term (10 yr) AZT/3TC/LPV/r RPV/DRV/r or AZT/3TC/DRVr
13 Rationale for prioritisation LPVr 4-in-1: first line for under 3 years to address the lack of optimal formulations EFV triple: first line 3-10 years to provide an FDC to maximise adherence and simplify procurement ATVr and DRVr: use in 2 nd and 3 rd line formulations and overcome issue with separate administration of RTV RAL better formulation: use in infants and young children to enable rapid introduction of INI for use in 1 st line regimen DTG single or FDCs: identified as key drug to introduce INI in first line with potential for harmonisation across the full age spectrum NVP 20 mg: better dosage form to facilitate dosing for PnP TAF: key drug for future use in 1 st line to minimise toxicity with potential for harmonization across the full age spectrum
14 Progress made since Dec 2014 New Guidelines: more prominent role of integrase inhibitors and ATVr as an alternative to LPVr in 2 nd line use. New products: LPVr pellets FDA approved Better access: Merck agreement with MPP on RAL Advances in FDC development: PHTI projects Progress of ongoing research: P1093 and new protocols More communication: SRAs consulted to advocate for PADO priorities and to explore regulatory pathways for key FDC More guidance: IATT policy briefs on LPVr pellets Impact in countries: PAPWG commitment has resulted in most countries with high burden to procure optimal products MPP= Medicine Patent Pool; PHTI= Paediatric HIV Treatment Initiative; SRAs: stringent regulatory agencies; IATT= Interagency Task Team; PAPWG= Paediatric ARV Procurement Working Group; CTA=Commitment To Action.
15 Thinking strategically about 1st line 0-4 weeks 4 wks-3 years 3-10 years years NOW RAL DTG single or DTG/ABC/3TC LPVr 4-in-1 RAL better formulation DTG single or DTG/ABC/3TC EFV/ABC/3TC DTG single or DTG/ABC/3TC DTG/ABC/3TC or DTG/TDF/XTC DTG/TAF/XTC DTG/TAF/XTC DTG/TAF/XTC DTG/TAF/XTC FUTURE
16 Short term (1-2 years)
17 Mid term (2-5 years)
18 Adult ART optimization - key events ( ) June 2010: Conference on dose optimization ("CADO I") April 2011: Priorities for ART optimization ( Tx 2.0 short term priorities) Nov 2011: ART sequencing meeting May 2012: Think Tank for ART optimization ( Tx 2.0 medium term priorities) April 2013: Conference on drug optimization ("CADO II") Mar 2014: Think Tank" for HIV treatment optimization (implications for future reviews of WHO guidelines) Mar 2015: Think Tank" for treatment optimization of HIV and Hepatitis C Feb 2016: Think Tank" for treatment optimization of HIV (AAWG and PAWG joint meeting)
19 WHO ARV Guidelines Evolution from 2002 to 2015 Topic When to start CD4 200 CD4 200 CD Consider CD4 350 for TB CD Regardless CD4 for TB and HBV CD Regardless CD4 for TB, HBV PW and SDC - CD4 350 as priority ART initiation at any CD4 cell count 1 st Line ART 2 nd Line ART 3 rd Line ART Viral Load Testing 8 options - AZT preferred Boosted and nonboosted PIs 4 options - AZT preferred Boosted PIs -IDV/r LPV/r, SQV/r 8 options - AZT or TDF preferred - d4t dose reduction Boosted PI - ATV/r, DRV/r, FPV/r LPV/r, SQV/r 6 options & FDCs - AZT or TDF preferred - d4t phase out Boosted PI - Heat stable FDC: ATV/r, LPV/r 1 preferred option & FDCs - TDF and EFV preferred across all pops Boosted PIs - Heat stable FDC: ATV/r, LPV/r Continue with FDC approach and phased introduction of new options (DTG, EFV 400 ) Add more heat stable PI options (DRV/r) and new strategies (NRTI sparing regimens) None None None DRV/r, RAL, ETV DRV/r, RAL, ETV Encourage HIV DR to guide No No (Desirable) Earlier initiation Simpler treatment Less toxic, more robust regimens Yes (Tertiary centers) Yes (Phase in approach) Better and simpler monitoring Yes (preferred for monitoring, use of PoC, DBS) Support for scale up of VL using all technologies WHO, 2015
20 2015 Consolidated ARV Guidelines New drug options Phased introduction of new alternative ARV options in 1 st and 2 nd line (dolutegravir, low dose efavirenz and heat stable darunavir/ritonavir ) Lower toxicity Better resistance profile Pill size and cost reduction potential Safety and efficacy in PLHIV with TB and pregnant women still under evaluation Generic single formulations and FDCs expected to be available in 2017/2018
21 Current Role of New ARV Options in 2015 WHO Guidelines ARV Population 1 st line 2 nd line 3 rd line Comments EFV 400 Adult/Adol DTG RAL Adult/Adol Children No dose reduction studies in children is needed (already pk adjusted). Not approved in children less than 12 years old. Twice daily dose probably needed in TB patients using RMP Adult/Adol Currently preferred as 3 rd line option in adults and as 2 nd line option in children Children Limited use as alternative 2 nd line option in adults. (RAL+ LPV/r) DRV/r Adult/Adol Currently preferred as 3 rd Children line option.
22 What are the challenges that prevented further innovation in 2015 Consolidated Guidelines? EFV 400 lack of efficacy data in TB and PW DTG RAL DRV/r TAF lack of safety data in PW lack of efficacy in TB lack of safety and efficacy in children lack of efficacy data in 2 nd line (adult and children) lack of efficacy data in 1 st line for children lack of generic production of age appropriate formulations lack of heat stable formulations harmonization in DRV/RTV ratio among adults and children (6:1 in children vs 8:1 in adults) Lack of efficacy and safety data in TB, PW and children
23 2016 WHO Think Tank on Treatment Optimization: Key Messages Safety and efficacy of DTG, EFV 400 and TAF in pregnant women, children and TB coinfection trials with DTG and EFV400 ro provide evidence by 2017/2018. Lack of safety and efficacy data for TAF use in PW and children Concerns about drug interactions between TAF and RIF- Studies needed Impact of HIVDR in transition to new regimens Moderate support to move away from NNRTI to INSTIs in presence of >15% prevalence resistance to NNRTIs among ART starters Achieving moderate to high national viral load coverage more important than individual HIVDR testing Treatment Optimization of HIV (2016 AAWG and PAWG Joint Meeting) Feb 21, 2016 (18:00-22:00 hs) Westin Copley Hotel Boston USA Two drug treatment strategies (switching & long acting ARVs) Lower support for switch /simplification strategies using PI+3TC and DTG+RIL; moderate support for DTG+3TC. Highlights need for 2 nd line ART studies with new combinations as DRV/r+ DTG Confidence that long acting ARV treatments containing two drugs seems to be sufficient access programmes in the future
24 Long acting ARVs - The emergence of Long Acting ARVs is exciting & great interest to the HIV community - Main focus on prevention but interest also in treatment - 2 drugs currently in clinical trials (PK and PK-PD): - Rilpivirine LA - Cabotegravir - Particular use in special/vulnerable populations with poor adherence or difficult to treat - Administration at least monthly but preferably longer - Need to understand mechanisms of entry from depot into systemic circulation and reasons for variability.
25 NEW RATIONALE TO SIMPLIFY /OPTIMIZE THE EOI LIST FOR ANTIRETROVIRAL DRUGS AND FORMULATIONS For inclusions in EoI-HIV: New ARV drugs or new formulations of existing drugs: drugs and formulations that are newly included in the most recent WHO guidelines or prioritized by adult and paediatric ARV optimization working groups (AAWG and PAWG) For deletions in EoI-HIV: Adult ARVs: a) products with five or more of manufacturers already prequalified by WHO b)standalone formulations and co-blister packs of ARVs currently recommended in WHO consolidated guidelines which already exist in dual and /or triple fixed dose combinations Paediatrc ARVs: a) products not included in the Optimal and Limited use list as defined by the 2016 IATT formulary b) products with three or more of manufacturers already WHO prequalified
26 HIV Drug Resistance (HIVDR) Surveillance data from revealed pre-treatment (PDR) HIVDR increased over time in LMIC and estimated that to be 6.8% in Increase levels of NNRTI PDR have emerged in several LMIC including: Angola (16%), Cuba (22%), Papua New Guinea (16%), Argentina (11%), Mexico (11%), Botswana (10%). A recent survey from another African country show NNRTI PDR >15%. Wide implementation of newly released WHO HIV Consolidated Guidelines on Treat All and PrEP, while reducing HIV incidence, are likely to further increase HIVDR prevalence. While the concern of HIVDR should not stop from providing ARVs to all in need, the long-term implications of earlier initiation on adherence and HIVDR need to be closely monitored. WHO recommends that ART scale up should be accompanied by routine HIVDR Surveillance; no indication for individual HIVDR
27 WHO HIVDR Surveillance and Monitoring Early Warning Indicators Pretreatment HIVDR HIVDR surveillance and Monitoring Acquired HIVDR Infants <18 months ART-naive
28 Outline What s new in ARV Guidelines Drug optimisation PADO priority list 2015 CROI 2016 Think Thank Meeting EOI 2016 list HIVDR Moving forward
29 Moving forward Opportunity for innovation in mid-2017 DTG could become preferred first-line regimen across age groups and as an option for second line Rethink the role of TAF in drug optimization (if indeed important rifampicin drug interaction) Need to review study design and inclusion criteria to enable more rapid uptake of innovations in WHO guidelines (ie. TB co-infection, PW) Advance the drug optimization agenda (CADO 3 and PADO3 in 2016)
30 08/03/
Existing and most needed paediatric ARV formulations
Existing and most needed paediatric ARV formulations Martina Penazzato Paediatric HIV advisor WHO HIV Department, Geneva Mach 7th 2016 Paediatric coverage still lags behind 45 40 35 30 25 20 15 10 5 0
More informationOverview of 2013 WHO consolidated ARV guidelines and update plans. Marco Vitoria HIV/AIDS Department WHO Geneva September 2014
AMDS ANNUAL STAKEHOLDERS AND PARTNERS MEETING Overview of 2013 WHO consolidated ARV guidelines and update plans Marco Vitoria HIV/AIDS Department WHO Geneva September 2014 AMDS ANNUAL STAKEHOLDERS AND
More informationUpdate on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges
Update on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges Treatment and Care Team Meg Doherty, Marco Vitoria, Martina Penazzato,
More informationMedical Challenges of HIV/AIDS pandemic: The WHO perspective. SOLTHIS HIV Forum
Medical Challenges of HIV/AIDS pandemic: The WHO perspective SOLTHIS HIV Forum Marco Vitoria HIV/AIDS Department World Health Organization September 2013 Topic 2002 2003 2006 2010 2013 When to start 1
More informationImmediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts)
Immediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts) Roselyne TOBY,MD, ID specialist Infectious Disease Unit/Yaounde Central Hospital
More informationProgress toward Universal ART Access: Innovations and Treatment 2.0. Marco Vitoria World Health Organization September 2013
Progress toward Universal ART Access: Innovations and Treatment 2.0 Marco Vitoria World Health Organization September 2013 The need for scalable, more efficient treatment models Simpler drugs Point of
More informationPRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT
PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT Dr Chewe Luo MMed (Paeds), Mtrop Paed, PhD Senior Adviser and Team Leader Country Programme Scale up HIV Section Programme Division UNICEF, NY
More informationTRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES
POLICY BRIEF HIV TREATMENT TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES JULY 2017 WHO This policy brief provides advice on a phased approach to transitioning to new WHO-recommended HIV treatment
More informationIs current first line ART good enough? Francois Venter Wits Reproductive Health & HIV Research Institute
Is current first line ART good enough? Francois Venter Wits Reproductive Health & HIV Research Institute Results: by April 2011 Budget: $3.5 billion 80% of 3,686 health facilities providing ARVs 50% ARV
More informationNew Directions on WHO ARV Guidelines 2018
New Directions on WHO ARV Guidelines 2018 Elaine Abrams Co-chair WHO Guidelines Development Group ICAP at Columbia University, New York Martina Penazzato Paediatric lead for the HIV Department World Health
More informationAdvancing Treatment 2.0: Progress on the 2013 Consolidated Guidelines What s new
Advancing Treatment 2.0: Progress on the 2013 Consolidated Guidelines What s new H I V / A I D S D e p a r t m e n t WHO HQ Meg Doherty, MD, MPH, PhD Coordinator Treatment and Care November 5, 2012 1 Overview
More informationART Optimization (New emerging molecules) KPA PRE-CONFERENCE 24 th April 2018 Dr Justine Jelagat Odionyi (EGPAF)/Dr Virginia Karanja(CHS)
ART Optimization (New emerging molecules) KPA PRE-CONFERENCE 24 th April 2018 Dr Justine Jelagat Odionyi (EGPAF)/Dr Virginia Karanja(CHS) Outline Introduction New ART molecules already adopted Dolutegravir
More informationUnmet needs and challenges of current ART in South Africa. Michelle Moorhouse 21 Nov 2015
Unmet needs and challenges of current ART in South Africa Michelle Moorhouse 21 Nov 2015 SA Snapshot Òct 2015 6-7 million HIV-positive: 18% world total, 25% of Southern Africa 3.2 on first line ART: consume
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationChallenges along the paediatric ARV pipeline Summary: IAS-ILF Industry Roundtable on Paediatric ARVs. Presented by Shaffiq Essajee (CHAI, USA)
Challenges along the paediatric ARV pipeline Summary: IAS-ILF Industry Roundtable on Paediatric ARVs Presented by Shaffiq Essajee (CHAI, USA) Optimize paediatric ARVs and shape the market PADO New drugs,
More informationReview of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA
Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo MMed
More informationForecasting pipeline ARVs. Joseph Perriëns Sandeep Juneja Aastha Gupta
Forecasting pipeline ARVs Joseph Perriëns Sandeep Juneja Aastha Gupta Presently: lack of visibility causes a gap between demand and generic production for new drugs Patent Holder R&D Marketing 3-4 yrs
More informationIATT Optimal List of Paediatric ARV Formulations: Background and Update
IATT Optimal List of Paediatric ARV Formulations: Background and Update Nandita Sugandhi Clinton Health Access Initiative, USA PADO/IATT Update for ARV Manufacturers October 19, 2015 Overview Rationale
More information2009 Revisions of WHO ART Guidelines. November 2009
2009 Revisions of WHO ART Guidelines November 2009 Guidelines Development Process 01/09 2009 WHO ART guideline revision process Scope of the work 03/09 WHO Guideline review committee approval 04/09 05/09
More informationPatient Forecasts for Pipeline ARVs: Adults
Patient Forecasts for Pipeline ARVs: Adults Presented at: WHO/UNAIDS Annual Meeting with ARV Manufacturers and Stakeholders March 19-20, 2015 Vineet Prabhu Market Intelligence Team, CHAI HIV Access Program
More informationARV Consolidated Guidelines 2015
ARV Consolidated Guidelines 2015 This document outlines the draft list of PICO questions to support systematic review process for the 2015 ARV guidelines process. PICO questions are grouped by clinical
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationUpdate on the IATT Paediatric Formulary. WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland
Update on the IATT Paediatric Formulary WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland Summary The Challenge Rationale for Paediatric ARV Formulary Optimization 2015 Revised
More informationTreatment Optimisation Community Condultation Feedback. KENLY SIKWESE AFRICAN COMMUNITY ADVISORY BOARD (AFROCAB) 3 rd May 2016
Treatment Optimisation Community Condultation Feedback KENLY SIKWESE AFRICAN COMMUNITY ADVISORY BOARD (AFROCAB) 3 rd May 2016 INTRODUCTION A brief history of ART 1987-90s AZT vecomes available ddi/ddc
More informationThe Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations
Slide 1 The Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations Sébastien Morin (International AIDS Society, Switzerland) 9 th
More informationList of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013
List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and
More informationUnderstanding the unmet medical needs with current ART
Thanks: Polly Clayden, Francesca Conradie, Loyd Mulenga, Gary Maartens, Andrew Hill, David Ripin, Elli Katabira, Chris Duncombe, Nathan Ford, Marco Vitoria, WHO, Trip Gullik Industry: Gilead, Janssen,
More informationUpdate on global guidelines. and emerging issues on perinatal HIV prevention. WHO 2013 Consolidated ARV Guidelines
WHO 2013 Consolidated ARV Guidelines Update on global guidelines H I V / A I D S DEPARTMENT and emerging issues on perinatal HIV prevention Children & HIV, St. Petersburg, Russia Sept 25-26, 2014 Dr. Nathan
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationPaediatric ART Working Group. guideline review meetings
Paediatric ART Working Group Report back from Sept 2009 and Dec 2009 ART guideline review meetings Paediatric ARV working group priorities Continue to emphasise need for scored adult FDCs this avoids need
More informationWhat is Treatment Optimisation (TO)
Outline What is treatmen optimisation Why is treatment optimisation important for the future of HIV treatment and care Drugs optimisation Some strategies for moving the TO agend forward Discussion: Why
More information2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents. When to Start and What ART to Use in 1 st and 2 nd Line December 2009
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents When to Start and What ART to Use in 1 st and 2 nd Line December 2009 Historic Evolution of CD4 Criteria for ART Initiation in
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationWhat next? Francois Venter. ART new drugs, new studies. Wits Reproductive Health & HIV Institute
Thanks: Polly Clayden, Francesca Conradie, Loyd Mulenga, Gary Maartens, Andrew Hill, David Ripin, Elli Katabira, Chris Duncombe, Nathan Ford, Marco Vitoria, WHO Industry: Gilead, Janssen, ViivV Abbott,
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationOptimizing Paediatric and Adolescent ART: Challenges and Opportunities
Optimizing Paediatric and Adolescent ART: Challenges and Opportunities Dr Nandita Sugandhi ICAP at Columbia University PATA 2017 Continental Summit 24 October, 2017 Johannesburg South Africa Overview What
More informationAchieving the 3 rd 90 in PEPFAR-supported countries:
Center for Global Health Achieving the 3 rd 90 in PEPFAR-supported countries: What will it take? Is it enough? Elliot Raizes, MD Division of Global HIV and TB Centers for Disease Control and Prevention
More informationDEPARTMENT. Treatment Recommendations for. Pregnant and Breastfeeding Women: Critical Issues Consolidated ARV Guidelines. Dr.
2013 Consolidated ARV Guidelines H I V / A I D S Treatment Recommendations for DEPARTMENT Pregnant and Breastfeeding Women: Critical Issues Dr. Nathan Shaffer Objectives of Presentation obackground ooverview
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationhiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants
hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments
More informationTreat All : From Policy to Action - What will it take?
Strategy Finance Integration Cascade of services People centred Political Will Treat All : From Policy to Action - What will it take? Thursday, 9 June, 13.00 14.30 Conference Room 11, United Nations Questions
More informationNew Directions in the 2015 Consolidated ARV Guidelines Update. Meg Doherty, MD, PhD, MPH 19 July 2015 WHO Satellite Vancouver IAS 2015
New Directions in the 2015 Consolidated ARV Guidelines Update Meg Doherty, MD, PhD, MPH 19 July 2015 WHO Satellite Vancouver IAS 2015 Objectives of Presentation 2015 ARV Guidelines update - why now? Overview
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More informationPaediatric ARV Procurement Working Group Progress Review at 31 December 2015
Paediatric ARV Procurement Working Group Progress Review at 31 December 2015 Version 4 March 2015 Updated with complete 2015 data from version presented at the January 27 2016 PAPWG meeting PAPWG Reporting
More information2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall
2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall Paediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationINTRODUCTION. WHO/Christopher Black
INTRODUCTION WHO/Christopher Black 7 1. BACKGROUND In 2016, an estimated 2.1 million children younger than 15 years and 17.8 million women were living with HIV worldwide (1). Despite advances in antenatal
More informationHIV und AIDS- was gibt es Neues für die Arbeit vor Ort?
HIV und AIDS- was gibt es Neues für die Arbeit vor Ort? Dr. med. Ralf Weigel Liverpool School of Tropical Medicine ralf.weigel@lstmed.ac.uk foring UPDATE 2017 Humanitäre Hilfe und Entwicklungszusammenarbeit
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationCan we make first line ART better?
Can we make first line ART better? Dr Angela Hartwig 8 th SA AIDS Conference, Durban Skills Building Session 15 June 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationScaling Up Treatment in Zimbabwe: The path to high coverage
Scaling Up Treatment in Zimbabwe: The path to high coverage IAS Conference Dr. Tsitsi Mutasa-Apollo ART Programme Coordinator, Zimbabwe 30 th June, 2013 Kuala Lumpur, Malaysia Outline Introduction Background
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationCurrent challenges of paediatric HIV care Experiences in Sub-Saharan Africa. Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya
Current challenges of paediatric HIV care Experiences in Sub-Saharan Africa Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya Current Challenges of Paediatric HIV Care What is Happening in the
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationEfavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town
Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile
More informationUNICEF/Malawi/2015/Schermbrucker. policy brief 2016 UPDATE
UNICEF/Malawi/2015/Schermbrucker policy brief IATT PAEDIATRIC ARV FORMULARY AND LIMITED-USE LIST: 2016 UPDATE BACKGROUND Delivery of antiretroviral treatment (ART) to children living with HIV is associated
More informationWHO mission on ART optimization in Belarus March 30-31, April 1, 2016
WHO mission on ART optimization in Belarus March 30-31, April 1, 2016 April, 2016 By Matti Ristola, Helsinki University Hospital, Finland, Valentin Rusovich, WHO Country Office, Belarus, Jens Lundgren
More informationMODERN ART FOR AFRICA
MODERN ART FOR AFRICA March 2018 A guide for HIV treatment activists and communities in lowand middle-income countries ART today A pricing agreement was recently announced that will speed up access to
More informationImpact of ART resistance in sub Saharan Africa
Impact of ART resistance in sub Saharan Africa Elliot Raizes, MD Division of Global HIV/TB US Centers for Disease Control and Prevention ITREMA Resistance Training Workshop 24 October, 2018 Center for
More informationCan we make first line ART better?
Can we make first line ART better? Dr David Stead Treatment Optimization HIV Clinicians Society Workshop 25 November 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationWHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?
WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES? Today s Webinar will be starting soon For the audio portion of this meeting: Dial 1-855-702-5382 Enter participant code 596-825-4701# Guidelines for online
More informationPaediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University of Cape Town
A Public Sector Antiretroviral Treatment Programme for Treatment-Experienced Children and Adolescents in the Western Cape Province of South Africa Using Darunavir/Ritonavir-, Raltegravir- and Etravirine-Containing
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationHIV & AIDS IN SOUTH AFRICA: WHERE ARE WE AND WHAT ARE
HIV & AIDS IN SOUTH AFRICA: WHERE ARE WE AND WHAT ARE THE REMAINING CHALLENGES DR YOGAN PILLAY, NDOH SA HIV CLINICIANS SOCIETY CONFERENCE, CAPE TOWN 25 NOVEMBER, 2012 GLOBAL DATA 34m people living with
More informationAccelerating Access to Simpler, Safer, and More Affordable HIV Treatment Through ART Optimization
Accelerating Access to Simpler, Safer, and More Affordable HIV Treatment Through ART Optimization What is antiretroviral treatment (ART) optimization? At its core, ART optimization is about ensuring that
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationARV Market Report. The State of the Antiretroviral Drug Market in Low- and Middle-Income Countries. ISSUE 4, November 2013
ARV Market Report The State of the Antiretroviral Drug Market in Low- and Middle-Income Countries ISSUE 4, November 213 ARV Market Report Clinton Health Access Initiative 1 Table of Contents TABLE OF EXHIBITS...
More informationINTERNAL QUESTIONS AND ANSWERS DRAFT
WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION Background: INTERNAL QUESTIONS AND ANSWERS DRAFT At the end of 2012, 9.7 million people were receiving
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationRationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi
Rationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi Presented by: Nandita Sugandhi M.D. 6 th International Workshop on HIV Pediatrics July
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationTreatment and Care: Product portfolio
Treatment and Care: Product portfolio Dr Paula Munderi MRC/UVRI Uganda Research Unit on AIDS EDCTP Stakeholder Meeting on HIV/AIDS 3-4 September 2013 Summary Brief overview HIV Treatment Pipeline Key Questions
More informationUPDATE ON THE CLINICAL MANAGEMENT OF HIV IN BARBADOS
UPDATE ON THE CLINICAL MANAGEMENT OF HIV IN BARBADOS 82 nd UWI/ BAMP CME November 18th and 19th, 2017 Tiffany Jordan, MB BS Locum Clinical Medical Officer, Ladymeade Reference Unit OBJECTIVES 1. Epidemiology
More informationHIV and contraception the latest recommendations
1 8-11 June 2015, Chiang-Mai HIV and contraception the latest recommendations Mary Lyn Gaffield, Sharon Phillips, Rachel Baggaley, Petrus Steyn, and Marleen Temmerman 2 Medical eligibility criteria for
More informationSUMMARY BRIEF: SIX KEY QUESTIONS AND ANSWERS
INTERNAL BRIEFING AND QUESTIONS AND ANSWERS KIT ON THE LAUNCHES OF WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION, 2013 AND GLOBAL UPDATE ON HIV
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationCONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION WHAT S NEW
POLICY BRIEF CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION WHAT S NEW NOVEMBER 2015 WHO Library Cataloguing-in-Publication Data Policy brief: consolidated
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationUpdates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013
Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationHIV Treatment for Adults and Adolescents. Stefano Vella MD Istituto Superiore di Sanità - Rome - Italy
HIV Treatment for Adults and Adolescents Stefano Vella MD Istituto Superiore di Sanità - Rome - Italy www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 PLHIV in need of ART WHO 2013 Guidelines
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationSupporting Sustained Supply through the Coordinated Procurement of ARVs
Supporting Sustained Supply through the Coordinated Procurement of ARVs ARV Procurement Working Group Newsletter April 2018 Introduction Through quarterly order cycles and business calls, the APWG has
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationAPACC 2016 HIV drug resistance. Shinichi Oka, MD, PhD. AIDS Clinical Center (ACC) National Center for Global Health and Medicine (NCGM)
APACC 2016 HIV drug resistance Shinichi Oka, MD, PhD. AIDS Clinical Center (ACC) National Center for Global Health and Medicine (NCGM) HIV drug resistance 1. Current situation of ART and TDR in Japan 2.
More informationInvesting for Impact Prioritizing HIV Programs for GF Concept Notes. Lisa Nelson, WHO Iris Semini, UNAIDS
Investing for Impact Prioritizing HIV Programs for GF Concept Notes Lisa Nelson, WHO Iris Semini, UNAIDS Top 5 Lessons Learned 1 2 3 4 5 Prioritize within the allocation amount Separate above allocation
More informationPersistent low level viraemia on third line ART
Persistent low level viraemia on third line ART Dr Richard Lessells XXVII International workshop on HIV drug resistance and treatment strategies October 2018 46-year old HIV-positive female HIV diagnosis
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationAdult Guidelines. Sipho Dlamini. Division of Infectious Diseases & HIV Medicine University of Cape Town Groote Schuur Hospital
Adult Guidelines Sipho Dlamini Division of Infectious Diseases & HIV Medicine University of Cape Town Groote Schuur Hospital Cape Town CME 3 rd June 2017 Sports Science Institute, Newlands Outline of talk
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More information